Letter from the ESC Congress Programme Committee Chair

Dear Colleagues,

We are delighted to present this special issue of ESC Congress 2017 in Review, focused on peripheral arterial diseases, which are increasingly prevalent in clinical practice and may be challenging to manage. The peer-reviewed highlights in this issue are based on presentations at the European Society of Cardiology (ESC) Congress 2017 held in Barcelona, Spain.

Within this issue, you will find a closer look at the newly published 2017 ESC Clinical Practice Guidelines on the diagnosis and treatment of peripheral arterial diseases, which cover arterial disease in every location except for the coronary and intracranial arteries as well as the aorta.

The Hot Line trials and late-breaking registry results presented in this issue include the COMPASS study which demonstrated that the combination of rivaroxaban 2.5 mg BID plus aspirin was superior to rivaroxaban 5 mg BID or aspirin alone in reducing the primary outcome of major adverse cardiac events, as well as the key outcome for PAD, major adverse limb events (defined as severe limb ischaemia leading to an intervention and major amputation due to vascular insufficiency above the forefoot).

We hope that the articles and practical perspectives presented in ESC Congress 2017 in Review - Focus on Interventions and Peripheral Circulation will provide you with new insights. Please be advised that in order to access ESC Congress content (videos, slides, abstracts, and reports) all year long, visit us online at any time at www.escardio.org/365.

We hope to see you in Munich for ESC Congress 2018. For more information, please visit www.escardio.org/ESC2018.

Professor Stephan Achenbach, FESC
Chairman, ESC Congress Programme Committee 2016-2018



Posted on 30 August, 201717 March, 2021